Secretory leukocyte protease inhibitor plays an important role in the regulation of allergic asthma in mice

Journal of Immunology

Volumn 186, Issue 7, 2011, Pages 4433-4442

  Marino, Rafael ^a   Thuraisingam, Thusanth ^b   Camateros, Pierre ^a   Kanagaratham, Cynthia ^a   Xu, Yong Zhong ^a   Henri, Jennifer ^c   Yang, Jingxuan ^d   He, Guoan ^e   Ding, Aihao ^e   Radzioch, Danuta ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d ETH ZURICH   (Switzerland)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B BETA; IMMUNOGLOBULIN E; MESSENGER RNA; RESIQUIMOD; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

AIRWAY RESISTANCE; ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPERPLASIA; CONTROLLED STUDY; DRUG EFFICACY; EOSINOPHILIA; GOBLET CELL; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE; WILD TYPE;

ACUTE DISEASE; ALLERGENS; ANIMALS; ASTHMA; BRONCHIAL HYPERREACTIVITY; CELL MOVEMENT; DISEASE MODELS, ANIMAL; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR;

EID: 79955011126     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001539     Document Type: Article

References (51)

1. Myers, T. R. 2006. Use of heliox in children. Respir. Care 51: 619-631. (Pubitemid 46888374)
2. Wright, C. D., A. M. Havill, S. C. Middleton, M. A. Kashem, P. A. Lee, D. J. Dripps, T. G. O'Riordan, M. P. Bevilacqua, and W. M. Abraham. 1999. Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. J. Pharmacol. Exp. Ther. 289: 1007-1014. (Pubitemid 29191260)
3. Blais, L., M. F. Beauchesne, and S. Lévesque. 2006. Socioeconomic status and medication prescription patterns in pediatric asthma in Canada. J. Adolesc. Health 38: 607.-e9-e16.
4. Brown, R., F. Turk, P. Dale, and J. Bousquet. 2007. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 62: 149-153. (Pubitemid 46090296)
5. Burburan, S. M., D. G. Xisto, and P. R. Rocco. 2007. Anaesthetic management in asthma. Minerva Anestesiol. 73: 357-365. (Pubitemid 47180401)
6. Sorkness, R. L., E. R. Bleecker, W. W. Busse, W. J. Calhoun, M. Castro, K. F. Chung, D. Curran-Everett, S. C. Erzurum, B. M. Gaston, E. Israel, et al; National Heart, Lung, and Blood Institute Severe Asthma Research Program. 2008. Lung function in adults with stable but severe asthma: Air trapping and incomplete reversal of obstruction with bronchodilation. J. Appl. Physiol. 104: 394-403. (Pubitemid 351231486)
7. Shome, G. P., J. D. Starnes, III, M. Shearer, R. Kennedy, A. Way, A. Arif, and S. Prabhakar. 2006. Exhaled nitric oxide in asthma: Variability, relation to asthma severity, and peripheral blood lymphocyte cytokine expression. J. Asthma 43: 95-99. (Pubitemid 43879422)
8. Bandi, V., S. Velamuri, C. Sirgi, J. Wendt, R. Wendt, and K. Guntupalli. 2005. Deposition pattern of heliox-driven bronchodilator aerosol in the airways of stable asthmatics. J. Asthma 42: 583-586. (Pubitemid 41765309)
9. Eisenberg, S. P., K. K. Hale, P. Heimdal, and R. C. Thompson. 1990. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J. Biol. Chem. 265: 7976-7981.
10. Odaka, C., T. Mizuochi, J. Yang, and A. Ding. 2003. Murine macrophages produce secretory leukocyte protease inhibitor during clearance of apoptotic cells: Implications for resolution of the inflammatory response. J. Immunol. 171: 1507-1514. (Pubitemid 36900086)
11. Fakioglu, E., S. S. Wilson, P. M. Mesquita, E. Hazrati, N. Cheshenko, J. A. Blaho, and B. C. Herold. 2008. Herpes simplex virus downregulates secretory leukocyte protease inhibitor: A novel immune evasion mechanism. J. Virol. 82: 9337-9344.
12. Tomee, J. F., P. S. Hiemstra, R. Heinzel-Wieland, and H. F. Kauffman. 1997. Antileukoprotease: An endogenous protein in the innate mucosal defense against fungi. J. Infect. Dis. 176: 740-747. (Pubitemid 27360541)
13. Sagel, S. D., M. K. Sontag, and F. J. Accurso. 2009. Relationship between antimicrobial proteins and airway inflammation and infection in cystic fibrosis. Pediatr. Pulmonol. 44: 402-409.
14. Ramadas, R. A., L. Wu, and A. M. LeVine. 2009. Surfactant protein A enhances production of secretory leukoprotease inhibitor and protects it from cleavage by matrix metalloproteinases. J. Immunol. 182: 1560-1567.
15. Ashcroft, G. S., K. Lei, W. Jin, G. Longenecker, A. B. Kulkarni, T. Greenwell- Wild, H. Hale-Donze, G. McGrady, X. Y. Song, and S. M. Wahl. 2000. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat. Med. 6: 1147-1153.
16. Thuraisingam, T., H. Sam, J. Moisan, Y. Zhang, A. Ding, and D. Radzioch. 2006. Delayed cutaneous wound healing in mice lacking solute carrier 11a1 (formerly Nramp1): Correlation with decreased expression of secretory leukocyte protease inhibitor. J. Invest. Dermatol. 126: 890-901.
17. Jana, N. K., L. R. Gray, and D. C. Shugars. 2005. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: A role for SLPI in innate mucosal immunity. J. Virol. 79: 6432-6440. (Pubitemid 40617246)
18. McNeely, T. B., D. C. Shugars, M. Rosendahl, C. Tucker, S. P. Eisenberg, and S. M.Wahl. 1997. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90: 1141-1149. (Pubitemid 27314150)
19. Py, B., S. Basmaciogullari, J. Bouchet, M. Zarka, I. C. Moura, M. Benhamou, R. C. Monteiro, H. Hocini, R. Madrid, and S. Benichou. 2009. The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS ONE 4: E5006.
20. Wang, Z., T. Zheng, Z. Zhu, R. J. Homer, R. J. Riese, H. A. Chapman, Jr., S. D. Shapiro, and J. A. Elias. 2000. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J. Exp. Med. 192: 1587-1600.
21. Weldon, S., N. McGarry, C. C. Taggart, and N. G. McElvaney. 2007. The role of secretory leucoprotease inhibitor in the resolution of inflammatory responses. Biochem. Soc. Trans. 35: 273-276. (Pubitemid 46596488)
22. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1: 135-145. (Pubitemid 33741967)
23. Schnare, M., G. M. Barton, A. C. Holt, K. Takeda, S. Akira, and R. Medzhitov. 2001. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2: 947-950. (Pubitemid 32976167)
24. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376. (Pubitemid 37174535)
25. Greene, C. M., N. G. McElvaney, S. J. O'Neill, and C. C. Taggart. 2004. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect. Immun. 72: 3684-3687. (Pubitemid 38697804)
26. Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3: 196-200. (Pubitemid 34141451)
27. Gorden, K. K., X. X. Qiu, C. C. Binsfeld, J. P. Vasilakos, and S. S. Alkan. 2006. Cutting edge: Activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J. Immunol. 177: 6584-6587. (Pubitemid 44715019)
28. Moisan, J., P. Camateros, T. Thuraisingam, D. Marion, H. Koohsari, P. Martin, M. L. Boghdady, A. Ding, M. Gaestel, M. C. Guiot, et al. 2006. TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L987-L995. (Pubitemid 43725061)
29. Camateros, P., M. Tamaoka, M. Hassan, R. Marino, J. Moisan, D. Marion, M. C. Guiot, J. G. Martin, and D. Radzioch. 2007. Chronic asthma-induced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463. Am. J. Respir. Crit. Care Med. 175: 1241-1249. (Pubitemid 46905749)
30. Belkowski, S. M., J. D. Boot, M. A. Mascelli, Z. Diamant, L. de Garavilla, B. Hertzog, D. Polkovitch, M. Towers, A. Batheja, and M. R. D'Andrea. 2009. Cleaved secretory leucocyte protease inhibitor as a biomarker of chymase activity in allergic airway disease. Clin. Exp. Allergy 39: 1179-1186.
31. Ghasemlou, N., D. Bouhy, J. Yang, R. López-Vales, M. Haber, T. Thuraisingam, G. He, D. Radzioch, A. Ding, and S. David. 2010. Beneficial effects of secretory leukocyte protease inhibitor after spinal cord injury. Brain 133: 126-138.
32. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
33. Jin, F. Y., C. Nathan, D. Radzioch, and A. Ding. 1997. Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 88: 417-426. (Pubitemid 27131383)
34. Saglani, S., S. A. Mathie, L. G. Gregory, M. J. Bell, A. Bush, and C. M. Lloyd. 2009. Pathophysiological features of asthma develop in parallel in house dust mite exposed neonatal mice. Am. J. Respir. Cell Mol. Biol. 41: 281-289.
35. Lentsch, A. B., J. A. Jordan, B. J. Czermak, K. M. Diehl, E. M. Younkin, V. Sarma, and P. A. Ward. 1999. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am. J. Pathol. 154: 239-247. (Pubitemid 29031631)
36. Goodman, J. E., J. K. Chandalia, S. Thakali, and M. Seeley. 2009. Meta-analysis of nitrogen dioxide exposure and airway hyper-responsiveness in asthmatics. Crit. Rev. Toxicol. 39: 719-742.
37. Motomura, C., H. Odajima, J. Tezuka, Y. Murakami, Y. Moriyasu, N. Kando, N. Taba, D. Hayashi, K. Okada, and S. Nishima. 2009. Effect of age on relationship between exhaled nitric oxide and airway hyperresponsiveness in asthmatic children. Chest 136: 519-525.
38. Komatsu, Y., K. Fujimoto, M. Yasuo, K. Urushihata, M. Hanaoka, T. Koizumi, and K. Kubo. 2009. Airway hyper-responsiveness in young adults with asthma that remitted either during or before adolescence. Respirology 14: 217-223.
39. Hamelmann, E., J. Schwarze, K. Takeda, A. Oshiba, G. L. Larsen, C. G. Irvin, and E. W. Gelfand. 1997. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am. J. Respir. Crit. Care Med. 156: 766-775. (Pubitemid 27396413)
40. Hoymann, H. G. 2007. Invasive and noninvasive lung function measurements in rodents. J. Pharmacol. Toxicol. Methods 55: 16-26. (Pubitemid 46048679)
41. Fukunaga, J., M. Abe, A. Murai, Y. Akitake, M. Hosokawa, and M. Takahashi. 2007. Comparative study to elucidate the mechanism underlying the difference in airway hyperresponsiveness between two mouse strains. Int. Immunopharmacol. 7: 1852-1861. (Pubitemid 350138514)
42. Jonasson, S., G. Hedenstierna, H. Hedenström, and J. Hjoberg. 2009. Comparisons of effects of intravenous and inhaled methacholine on airway physiology in a murine asthma model. Respir. Physiol. Neurobiol. 165: 229-236.
43. Lougheed, M. D., T. Fisher, and D. E. O'Donnell. 2006. Dynamic hyperinflation during bronchoconstriction in asthma: Implications for symptom perception. Chest 130: 1072-1081. (Pubitemid 44583737)
44. Diegelmann, R. F., and M. C. Evans. 2004. Wound healing: An overview of acute, fibrotic and delayed healing. Front. Biosci. 9: 283-289. (Pubitemid 38925460)
45. Dragon, S., M. K. Takhar, L. Shan, K. T. Hayglass, F. E. Simons, and A. S. Gounni. 2009. T(H)2 cytokines modulate the IL-9R expression on human neutrophils. Biochem. Biophys. Res. Commun. 384: 167-172.
46. Corry, D. B., H. G. Folkesson, M. L. Warnock, D. J. Erle, M. A. Matthay, J. P. Wiener-Kronish, and R. M. Locksley. 1996. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J. Exp. Med. 183: 109-117. (Pubitemid 26028750)
47. Westin, U., E. Lundberg, and K. Ohlsson. 1998. IgE-mediated histamine release from nasal mucosa is inhibited by SLPI (secretory leukocyte protease inhibitor) to the level of spontaneous release. Mediators Inflamm. 7: 217-220. (Pubitemid 28338152)
48. Nakamura, A., Y. Mori, K. Hagiwara, T. Suzuki, T. Sakakibara, T. Kikuchi, T. Igarashi, M. Ebina, T. Abe, J. Miyazaki, et al. 2003. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)- deficient mice. J. Exp. Med. 197: 669-674. (Pubitemid 36314661)
49. Xu, W., B. He, A. Chiu, A. Chadburn, M. Shan, M. Buldys, A. Ding, D. M. Knowles, P. A. Santini, and A. Cerutti. 2007. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat. Immunol. 8: 294-303. (Pubitemid 46745379)
50. Jurk, M., F. Heil, J. Vollmer, C. Schetter, A. M. Krieg, H. Wagner, G. Lipford, and S. Bauer. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3: 499. (Pubitemid 34669818)
51. Taggart, C. C., S. A. Cryan, S. Weldon, A. Gibbons, C. M. Greene, E. Kelly, T. B. Low, S. J. O'Neill, and N. G. McElvaney. 2005. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J. Exp. Med. 202: 1659-1668. (Pubitemid 41815872)